Each year NAR Cancer publishes a collection on a key topic in the nucleic acids research and cancer fields. Browse recent collections:
- Translational Control in Cancer
- DNA Repair and Nucleic Acids Therapeutics
Submit your work to the next collection on manipulating DNA repair and the DNA damage response to improve cancer therapy. Find out more
Latest Articles
Targeted therapy leveraging synthetic lethality in homologous recombination (HR)-defective tumors, particularly in BRCA-mutated tumors through poly(ADP-ribose) polymerase (PARP)-dependent repair inhibition, has shown success. However, the challenge lies in the ability of the tumors to reactivate HR ...
N 6 -methyladenosine (m 6 A) is the most abundant internal RNA modification in eukaryotes and plays a key role in cellular growth and development. Global changes in cellular methylated RNA and m 6 A-mediated transcript regulation significantly impact oncogenesis. Here, we investigate how recurrent ...
Prostate cancer (PCa) is the second most common cancer worldwide and the fifth leading cause of cancer-related deaths among men. The emergence of metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) exemplifies the complex disease management for PCa. PARP ...
Platinum-based combination chemotherapy remains the backbone of first-line treatment for patients with advanced epithelial ovarian cancer (EOC). While most patients initially respond well to the treatment, patients with relapse ultimately develop platinum resistance. This study identified ...
SRSF2 (serine/arginine-rich splicing factor 2) is a critical regulator of pre-messenger RNA splicing, which also plays noncanonical functions in transcription initiation and elongation. Although elevated levels of SRSF2 are associated with advanced stages of lung adenocarcinoma (LUAD), the ...
Editor's Choice Articles
Oncogene activation in normal untransformed cells induces DNA replication stress and creates a dependency on DNA damage response (DDR) mechanisms for cell survival. Different oncogenic stimuli signal via distinct mechanisms in every cancer setting. The DDR is also pathologically reprogrammed and ...
The p53 tumor suppressor gene governs a multitude of complex cellular processes that are essential for anti-cancer function and whose dysregulation leads to aberrant gene transcription, activation of oncogenic signaling and cancer development. Although mutations can occur at any point in the ...
A subset of cancer cells are intrinsically sensitive to inhibitors targeting PARG, the poly(ADP-ribose) glycohydrolase that degrades PAR chains. Sensitivity is accompanied by persistent DNA replication stress, and can be induced by inhibition of TIMELESS , a replisome accelerator. However, the ...
Secreted protein acidic and rich in cysteine (SPARC), a conserved secreted glycoprotein, plays crucial roles in regulating various biological processes. SPARC is highly expressed and has profound implications in several cancer types, including melanoma. Understanding the mechanisms that govern ...
Neuroblastoma (NB) is the most common cancer in infancy with an urgent need for more efficient targeted therapies. The development of novel (combinatorial) treatment strategies relies on extensive explorations of signaling perturbations in neuroblastoma cell lines, using RNA-Seq or other high ...
Editor-in-Chief
William S. Dynan, PhD
Emory University School of Medicine
Atlanta, USA
Editorial Board
5th Anniversary Symposium: Manipulating DNA repair and the DNA damage response to improve cancer therapy
NAR Cancer is pleased to partner with Social DNAing webinar series, hosted by Columbia University, to present their 5th anniversary virtual symposium.
View the program and sign up for free today
Featured content
Translational Control in Cancer
Translational control plays a crucial role in supporting the metabolic needs of cancer cells, influencing ribosomal biogenesis, RNA-protein interactions, and non-coding RNA dynamics. These mechanisms drive tumor progression by enhancing protein synthesis, promoting survival, angiogenesis, and metastasis. Understanding these processes across different cancers and microenvironments reveals promising therapeutic targets. NAR Cancer features 11 review articles exploring translational control in cancer. Additionally, we have collected some previously published articles that speak to the importance of this topic as well.
Browse the collection
High-Impact Research Collection
Explore a collection of most cited and most read research from the past two years, plus browse the top performing articles from Altmetric published in NAR Cancer.
Browse the collection
Cancer Data Resource Articles
Discover a collection of cancer data resource articles, highlighting topics such as the first database that hosts millions of somatic motifs ascribed to a variety of sequence alteration mechanisms, to a single-cell inferred site-specific omics resource for tumor microenvironment association study.
Browse the articles
Editor's Choice Articles
Explore articles that have been hand-picked from Editor-in-Chief William Dynan, as the best research from NAR Cancer.
Browse the articles
Publishing with NAR Cancer
NAR Cancer: a journal for scientists by scientists
NAR Cancer is a fully open access journal publishing original research and review articles at the intersection of the nucleic acids and cancer fields. The editors of the journal are committed to rapid publication, a transparent and fair editorial process, and Open Science.
Find out why the journal is the perfect home for your cancer research
Interested in submitting your article?
All manuscripts are peer-reviewed and must meet the general criteria of originality, timeliness, significance, and scientific excellence. NAR Cancer publishes the following article types:
- Standard Articles - reporting original research results in a variety of cancer-relevant categories
- Review Articles - there are two categories of review articles: Critical Reviews and Perspectives & Short Reviews
- Cancer Data Resource Articles - includes a brief description of the resource, focusing on factual content and methods by which information can be accessed and retrieved
Visit our instructions to authors to learn more
Read and publish agreements
Oxford University Press has Read and Publish agreements with over 25 institutions and consortia around the world allowing affiliated researchers at participating institutions to:
- publish accepted articles open access in OUP journal, with their institutions covering the open access publication charge
- read high quality, high impact research from OUP's prestigious journals
Find out of your institution is participating
Promote your published work with NAR Cancer
As the author, you are the best advocate for your work and we encourage you to be involved in promoting your publication! Sharing your ideas and news about your publication with your colleagues and friends could take as little as 15 minutes and will make a real difference in raising the profile of your research.
View OUP's self-promotion guide & learn how OUP also works to promote your content
